The effect of chemotherapy on telomere dynamics: Clinical results and possible mechanisms

Leukemia and Lymphoma

Volumn 54, Issue 9, 2013, Pages 2023-2029

  Diker Cohen, Talia ^a,b   Uziel, Orit ^b   Szyper Kravitz, Martine ^c   Shapira, Hava ^d   Natur, Aiman ^e   Lahav, Meir ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d Hematocytologic Laboratory   (Israel)

^e MEIR MEDICAL CENTER   (Israel)

Author keywords

5 fluorouracil; Chemotherapy; Fludarabine; Hematopoietic stem cells; Lymphoma; Telomeres

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEMATOPOIETIC STEM CELL; HUMAN; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TELOMERE; TELOMERE SHORTENING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; FEMALE; FLUOROURACIL; HEMATOPOIETIC STEM CELLS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPE; MALE; MIDDLE AGED; NEOPLASMS; TELOMERE; VIDARABINE;

EID: 84882954562     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.757765     Document Type: Article

References (35)

1. P,Constine L, Greenberger J, et al. Hematopoietic stem cell compartment:Acute and late eff ects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys 1995;31:1319-1339.
2. Lerner C, Harrison DE. 5-Fluorouracil spares hemopoietic stem cells responsible for long-term repopulation. Exp Hematol 1990;18:114-118.
3. Hodgson GS, Bradley TR. Properties of haematopoietic stem cells surviving 5-fluorouracil treatment: Evidence for a pre-CFU-S cell? Nature 1979;281:381-382.
4. Berger MG, Berger J, Richard C, et al. Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization. Leukemia 2008;22:2131-2134.
5. Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006;99:690-705.
6. Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 2009;27:791-798.
7. Watson JD. Origin of concatemeric T7 DNA. Nat New Biol 1972;239:197-201.
8. Schwartz HS, Dahir GA, Butler MG. Telomere reduction in giant cell tumor of bone and with aging. Cancer Genet Cytogenet 1993;71:132-138.
9. Hastie ND, Dempster M, Dunlop MG, et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990;346:866-868.
10. Vaziri H, Schachter F, UchidaI, et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 1993;52:661-667.
11. Butler MG, Tilburt J, DeVries A, et al. Comparison of chromosome telomere integrity in multiple tissues from subjects at diff erent ages. Cancer Genet Cytogenet 1998;105:138-144.
12. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-413
13. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
14. Kolquist KA, Ellisen LW,Counter CM, et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 1998;19:182-186.
15. Vaziri H, Dragowska W, Allsopp RC, et al. Evidence for a mitotic clock in human hematopoietic stem cells: Loss of telomeric DNA with age. Proc Natl Acad Sci USA 1994;91:9857-9860.
16. Van Ziffle JA, Baerlocher GM, Lansdorp PM. Telomere length in subpopulations of human hematopoietic cells. Stem Cells 2003;21:654-660.
17. Wynn RF, Cross MA, Hatton C, et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet 1998;351:178-181.
18. Rufer N, Brummendorf TH, Chapuis B, et al. Accelerated telomere shortening in hematological lineages is limited to the first year following stem cell transplantation. Blood 2001;97:575-577.
19. Robertson JD, Testa NG,Russell N H, et al. Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplant 2001;27:1283-1286.
20. de Pauw ES, Otto SA, Wijnen JT, et al. Long-term follow-up of recipients of allogeneic bone marrow grafts reveals no progressive telomere shortening and provides no evidence for haematopoietic stem cell exhaustion. Br J Haematol 2002;116:491-496.
21. Lahav M, Uziel O, Kestenbaum M, et al. Nonmyeloablative conditioning does not prevent telomere shortening after allogeneic stem cell transplantation. Transplantation 2005;80:969-976.
22. Akiyama M, Asai O, Kuraishi Y, et al. Shortening of telomeres in recipients of both autologous and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2000;25:441-447.
23. Engelhardt M, Ozkaynak MF, Drullinsky P, et al. Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia 1998;12:13-24.
24. Franco S, Ozkaynak MF, Sandoval C, et al. Telomere dynamics in childhood leukemia and solid tumors :A follow-up study. Leukemia 2003;17:401-410.
25. M, Uziel O, Shapiro H, et al. Granulocyte colony-stimulating factor administration upregulates telomerase activity in CD34 haematopoietic cells and may prevent telomere attrition after chemotherapy. Br J Haematol 2003;120:329-336.
26. Lee JJ, Nam CE, Cho SH, et al. Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy. Ann Hematol 2003;82:492-495.
27. Unryn BM, Hao D,Gl?ck S, et al. Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer. Clin Cancer Res 2006;12:6345-6350.
28. Yoon SY, Sung HJ, Park KH, et al. Telomere length shortening of peripheral blood mononuclear cells in solid-cancer patients undergoing standard-dose chemotherapy might be correlated with good treatment response and neutropenia severity. Acta Haematol 2007;118:30-37.
29. Schruder CP, Wisman GB, de Jong S, et al. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer 2001;84:1348-1353.
30. Stewart FM, Temeles D, Lowry P, et al. Post-5-fluorouracil human marrow: Stem cell characteristics and renewal properties after autologous marrow transplantation. Blood 1993;81:2283-2289.
31. Visani G, Lemoli RM, Tosi P, et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999;105:775-779.
32. Sakoff JA, De Waal E, Garg MB, et al. Telomere length in haemopoietic stem cells can be determined from that of mononuclear blood cells or whole blood. Leuk Lymphoma 2002;43:2017-2020.
33. Rufer ND, Thornbury G, Roosnek E, et al. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol 1998;16:743-747.
34. Asai A, Kiyozuka Y, Yoshida R, et al. Telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells: Correlation with cell proliferation, diff erentiation and chemosensitivity to anticancer drugs. Anticancer Res 1998;18:1465-1472.
35. Roelofs H, de Pauw ES, Zwinderman AH, et al. Homeostasis of telomere length rather than telomere shortening after allogeneic peripheral blood stem cell transplantation. Blood 2003;101:358-362.